Clinical Trials Logo

Clinical Trial Summary

This trial is an open, phase II clinical study. The study is divided into two parts: A and B, and the part A evaluate the safety and tolerability of AZD4547 combined with Tislelizumab in patients with locally advanced or metastatic urothelial cancer, determine the recommended dose of midoral AZD4547 combined with Tislelizumab in a Chinese patient population. Part B study will evaluate the efficacy of this recommended dose combined with Tislelizumab in patients with locally advanced or metastatic urothelial cancer with FGFR2 / 3 alterations , and will also further evaluate the safety, tolerability, and PK and PD characteristics of AZD4547 in combination with Tislelizumab.


Clinical Trial Description

Part A of the study In Part A, subjects will receive AZD4547 80mg BID orally for cycles every 21 days and terelizumab 200mg will be an intravenous infusion (IV) 200mg every 3 weeks. Subsequent subjects in Part A should be administered at least 7 days after the first dose of the first subject (sentinel subject). . Tolerability will be assessed based on the incidence of dose-limiting toxicity (DLT) observed in cycle 1 (21 days). Part B; If a DLT event occurs in> 1 of the 6 DLT-evaluable subjects, With the consent of the investigator and the sponsor, An additional combined regimen cohort of six patients with a lower AZD4547 dose (AZD4547 60mg BID + Tislelizumab 200mg Q3W) will be initiated. I A specific dose / regimen of subjects and no more than one subject with DLT events will be selected to confirmation for confirmation for use in the Part B study. After cycle 1, subjects will continue to receive combination therapy in one cycle every 21 days until disease progression, death, loss to follow-up, voluntary withdrawal of informed consent, occurrence of intolerable toxicity, investigator decision to terminate treatment, or the end of the entire study. Safety assessments will be performed in each visit cycle, including the incidence and severity of adverse events (according to CTCAEv5.0) and laboratory abnormalities Study Part B Patients with locally advanced or metastatic urothelial carcinoma harboring FGFR2 / 3 alterations will follow the Simon's optimal two-stage design. It was considered "efficacy evaluable" when tumor assessment results were available at both baseline and after treatment ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05775874
Study type Interventional
Source Abbisko Therapeutics Co, Ltd
Contact Yuan Lu, Director
Phone 021-68910052
Email clinical@abbisko.cn
Status Recruiting
Phase Phase 2
Start date September 30, 2022
Completion date December 30, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Recruiting NCT04617756 - Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract Phase 2
Recruiting NCT06116396 - Liquid Biospy for Urinary Cancers
Recruiting NCT05723991 - Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma Phase 4
Active, not recruiting NCT03039413 - Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy Early Phase 1
Completed NCT02795156 - Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Phase 2
Terminated NCT03915405 - KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Completed NCT04452214 - A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT05911295 - Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Phase 3
Terminated NCT01093066 - Prospective Multicentric Evaluation of a Bladder Preservation Strategy Phase 2
Terminated NCT01042795 - Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy Phase 2
Recruiting NCT06022757 - Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) Phase 1/Phase 2
Recruiting NCT03212404 - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Phase 1
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Completed NCT04077359 - Prospective Trial for Examining Hematuria Using Computed Tomography N/A